Trial Condition(s):

Metastatic castration-resistant prostate cancer (mCRPC)

Analysis of Care for Patients with Castration-Resistant Prostate Cancer (CRPC)

Bayer Identifier:

18499

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

Study Completed

Trial Purpose

A retrospective secondary data analysis on clinical characteristics, treatment patterns and treatment costs, especially to identify Xofigo’s position in real life treatment pathway of CRPC patients.

Inclusion Criteria
:
 -  All patients with a final diagnosis of mCRPC (=indication for the treatment with Xofigo) archived in ContraCare’s reimbursement database
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
152
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers
No

Where to Participate

Locations
Status
LocationsStatus

Trial Design